Repros Therapeutics Inc (NASDAQ:RPRX) reported that vaginal administration of Proellex ® at doses of both 6 and 12 mg achieved significant reduction in excessive menstrual bleeding, the key symptom of uterine fibroids.
Normal menstrual blood loss in a menstrual cycle is approximately 35 mL. Woman experiencing blood loss of > 80 mL are considered to suffer from menorrhagia or excessive menstrual bleeding. In this small Phase 2b study, 13, 15 and 14 women with confirmed uterine fibroids were enrolled in the 6mg, 12mg and placebo arms, respectively. At baseline, the mean amount of blood lost for one menstrual cycle was 255 mL, 274 mL and 238 mL for each arm, respectively. The blood loss ranged from a low of 94 mL to a high of 654 mL. The most severe menstrual bleeding at baseline was observed in the 12 mg group. Blood loss was determined by collecting all sanitary products used from an individual and then an alkaline hematin assay was performed to estimate the actual amount of blood collected in the pads.
When a sufficient concentration of Proellex® is achieved in circulation, amenorrhea (cessation of menses) is achieved. Just over half, 52%, of Proellex®-treated subjects became amenorrheic with no evidence of a dose effect. All subjects treated with Placebo continued to menstruate throughout the 18 week dosing period. The p-value for this comparison is 0.0011. Bleeding diaries consistently report a statistically significant difference in the number of days of bleeding and bleeding intensity between those treated with Proellex® and Placebo.
Bleeding was also evaluated by PBAC (Pictorial Blood Assessment Chart). Subjects tallied sanitary product usage and stain size as guided by the chart. Proellex®-treated subjects reported a median 100% reduction in PBAC scores while Placebo-treated subjects reported a 25.4% reduction, further supporting the treatment affect associated with bleeding (p=0.0033).
Along with changes in menstrual patterns, fibroids measured by MRI were reduced in volume in the Proellex®-treated arms by 18% while the Placebo group showed continued increase in size, p= 0.0437.
The drug was generally well tolerated. Women in the drug arms continued to exhibit levels of estradiol consistent with bone preservation.
After the first 18 week treatment period, the women were withdrawn from drug to allow for menses. The women in the study are currently being treated with the second course of treatment for another 18 weeks. The study treatment assignment remains blinded to the subjects, physicians and those managing the study and data. The results of the second course of treatment should be reported within the next 5 months.
The Company believes Proellex® represents a significant advantage over GnRH agonists and antagonists in the treatment of uterine fibroids. Once both the vaginal and oral studies complete both 18 week courses of treatment the Company plans to request an end of Phase 2 meeting with the FDA to jointly discuss plans for Phase 3. (Original Source)
Shares of Repros jumped nearly 34% in after-hours trading. RPRX has a 1-year high of $9.65 and a 1-year low of $0.80. The stock’s 50-day moving average is $0.94 and its 200-day moving average is $2.22.
On the ratings front, Piper Jaffray analyst Joshua Schimmer reiterated a Hold rating on RPRX, with a price target of $2, in a report issued on February 8. The current price target represents a potential upside of 143.9% from where the stock is currently trading. According to TipRanks.com, Schimmer has a yearly average return of -16.8%, a 26.0% success rate, and is ranked #3784 out of 3787 analysts.
Repros Therapeutics, Inc. operates as a biopharmaceutical company, which focuses on the development of new drugs to treat hormonal and reproductive system disorders. The company’s current product pipeline consists of Androxal, Proellex, Vasomax and Z-Max. Repros Therapeutics was founded on August 20, 1987 and is headquartered in Woodlands, TX.